Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Prajwal Dhakal, Melissa L. Bates, Michael H. Tomasson, et al.
Blood Reviews (2022) Vol. 59, pp. 101036-101036
Closed Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
Dana Alawieh, Leila Cysique-Foinlan, Christophe Willekens, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
Keyuan Zhang, Xiang Zhang, Yang Xu, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 12
Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway
Hong Zheng, Ting Wu, Zhi Lin, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 5
Open Access | Times Cited: 3
Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
Dian Jin, Haoguang Chen, Jingsong He, et al.
Targeted Oncology (2024)
Open Access | Times Cited: 2
C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription
Mengbao Du, Mowang Wang, Meng Liu, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Combinations of HDAC inhibitor and PPAR agonist induce ferroptosis of leukemic stem cell-like cells in acute myeloid leukemia
Hui Zhou, Dongmei Qin, Chendi Xie, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 23, pp. 5430-5444
Closed Access | Times Cited: 2
Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia
Rebekka Wegmann, Ximena Bonilla, Ruben Casanova, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
Enrico Santinelli, Maria Rosaria Pascale, Zhuoer Xie, et al.
Blood Reviews (2023) Vol. 62, pp. 101130-101130
Closed Access | Times Cited: 6
Broadening the horizon: potential applications of CAR-T cells beyond current indications
Hendrik Karsten, Ludwig Matrisch, Sophia Cichutek, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Mitochondria inside acute myeloid leukemia cells hydrolyze ATP to resist chemotherapy
James T. Hagen, McLane M. Montgomery, Raphael Taiwo Aruleba, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm
Koichiro Fukuchi, Daisuke Koyama, Maki Takada, et al.
International Journal of Hematology (2023) Vol. 118, Iss. 4, pp. 489-493
Closed Access | Times Cited: 2
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 5, pp. 541-542
Open Access | Times Cited: 2
Potent and Selective BCL-XL Inhibitors and PROTAC Compounds as Potential Cancer Treatment and Immunotherapy
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 6, pp. 702-704
Open Access | Times Cited: 2
Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study
Zhibo Guo, Dan Guo, Desheng Kong, et al.
Hematology (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 2
Targeting BMAL1 reverse drug resistance of acute myeloid leukemia cells and promoting ferroptosis through HMGB1-GPX4 signaling pathway
Hong Zheng, Ting Wu, Zhi Lin, et al.
Research Square (Research Square) (2024)
Open Access
Progress of Venetoclax in Acute Myeloid Leukemia
贺 李
Advances in Clinical Medicine (2024) Vol. 14, Iss. 02, pp. 4004-4011
Closed Access
Vitamin K2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway
Tetsuzo Tauchi, Shota Moriya, Seiichi Okabe, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0307662-e0307662
Open Access
Increase in serum IL-4 in response to venetoclax therapy in xenograft models of acute myeloid leukaemia
D. A. Bogdanova, Vadim V. Shindyapin, Ekaterina D. Kolosova, et al.
Medical Immunology (Russia) (2024) Vol. 26, Iss. 4, pp. 827-834
Open Access
Identification of immunity- and ferroptosis-related signature genes as potential design targets for mRNA vaccines in AML patients
Chaojie Wang, Liping Lv, Ping Ma, et al.
Aging (2024) Vol. 16, Iss. 16, pp. 11939-11954
Open Access
The prognostic significance of genetics in acute myeloid leukemia under venetoclax-based treatment
Shan Zheng, Yuxin Tong, Linlin Yang, et al.
Annals of Hematology (2024)
Closed Access
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multi-center Cohort Study
Guopan Yu, Yu Zhang, Sijian Yu, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 87-97
Closed Access
Novel serous effusion-related risk models and biomarkers for predicting prognosis in T-cell lymphoma patients
Juanjuan Shang, Xiaoli Zhou, Bingyu Liu, et al.
Annals of Hematology (2024)
Closed Access
Conventional chemotherapy: millions of cures, unresolved therapeutic index
Anthony Letai, Hugues de Thé
Nature reviews. Cancer (2024)
Closed Access
Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML
Yi-zi Liu, Fenghong Zhang, Chun-xiao Hou, et al.
Hematology (2024) Vol. 30, Iss. 1
Open Access
Combinations of HDAC inhibitor and PPAR agonist induce ferroptosis of leukemia stem and progenitor cells in acute myeloid leukemia
Jie Zha, Hui Zhou, Dongmei Qin, et al.
Research Square (Research Square) (2023)
Open Access
Page 1 - Next Page

Scroll to top